OAK BROOK, Ill. – An automated system that uses artificial intelligence (AI) can quickly and accurately sift through breast MRIs in women with dense breasts to eliminate those without cancer, freeing up radiologists to focus on more complex cases, according to a study published in Radiology.
Mammography has helped reduce deaths from breast cancer by providing early detection when the cancer is most treatable. However, it is less sensitive in women with extremely dense breasts than in women with fatty breasts. In addition, women with extremely dense breasts have a three- to six-times higher risk of developing breast cancer than women with almost entirely fatty breasts and a twofold higher risk than the average woman.
Supplemental screening in women with extremely dense breasts increases the sensitivity of cancer detection. Research from the Dense Tissue and Early Breast Neoplasm Screening (DENSE) Trial, a large study based in the Netherlands, supported the use of supplemental screening with MRI.
"The DENSE trial showed that additional MRI screening for women with extremely dense breasts was beneficial," said study lead author Erik Verburg, M.Sc., from the Image Sciences Institute at the University Medical Center Utrecht in the Netherlands. "On the other hand, the DENSE trial confirmed that the vast majority of screened women do not have any suspicious findings on MRI."
Since most MRIs show normal anatomical and physiological variation that may not require radiological review, ways to triage these normal MRIs to reduce radiologist workload are needed.
In the first study of its kind, Verburg and colleagues set out to determine the feasibility of an automated triaging method based on deep learning, a sophisticated type of AI. They used breast MRI data from the DENSE trial to develop and train the deep learning model to distinguish between breasts with and without lesions. The model was trained on data from seven hospitals and tested on data from an eighth hospital.
More than 4,500 MRI datasets of extremely dense breasts were included. Of the 9,162 breasts, 838 had at least one lesion, of which 77 were malignant, and 8,324 had no lesions.
The deep learning model considered 90.7% of the MRIs with lesions to be non-normal and triaged them to radiological review. It dismissed about 40% of the lesion-free MRIs without missing any cancers.
"We showed that it is possible to safely use artificial intelligence to dismiss breast screening MRIs without missing any malignant disease," Verburg said. "The results were better than expected. Forty percent is a good start. However, we have still 60% to improve."
